As a downstream effector of activated FLT3 kinase, mTOR signaling has been implicated in the survival of FLT3-ITD+ AML cells, and aberrant activation of the mTOR pathway has been reported in FLT3-ITD AML cell lines that developed intrinsic resistance to FLT3 inhibitors through long-term culture with FLT3 inhibitor, coinciding with enhanced sensitivity to the combination of FLT3 and mTOR inhibitors (Lindblad et al., 2016; Damnernsawad et al., 2022). The gene discussed is FLT3; the disease is acute myeloid leukemia.